Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an ...

With market exclusivity for regular Eylea ending, the company has positioned its high-dose version, marketed with Bayer ...

Regeneron should weather the Eylea biosimilar launch storm and continue to deliver long-term shareholder value. See why REGN ...

While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based ...

Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...

This NMA serves to bridge the gap between trials for both therapies and compare them to one another based on existing data.

By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...

EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) stock is trading higher on Monday after the company revealed interim 16-week data ...

U.S. drugmaker Regeneron Pharmaceuticals on Thursday reported weaker-than-expected quarterly sales of the higher dose version ...

With “nerves of steel,” Amgen is getting ready to sell a copycat of Regeneron’s top-selling eye drug Eylea, even as ...

Canaccord Genuity analyst John Newman has maintained their bullish stance on REGN stock, giving a Buy rating today. John Newman has given his ...

After the Federal Circuit’s denial last month of Regeneron’s motion for an injunction pending appeal, seeking to prevent Amgen from ...